Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOE-105 in Adult Males With Childhood Onset Fluency Disorder (Orpheus)
NCT05583955Phase 2Completed
- Sponsor
- Noema Pharma
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of gemlapodect in childhood-onset fluency disorder (COFD), sponsored by Noema Pharma. Started Jul 2022; status: completed.
02
Drugs
gemlapodect
03
Conditions
childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on NCT05583955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583955.